BIVI

BioVie Inc

1.33

Oct 26 • 3:59 PM ET +0.09 (7.26%)

1.33

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: ANVS ALZN AVXL CGTX CRVO INMB ACOG ABOS ATHE PMN

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	11.34M
Enterprise Value	2.64M
Income	-22.12M
Sales	0.00M
Book/sh	1.36
Cash/sh	1.05
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	13
IPO	May 05, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.98
P/C	1.26
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.59
Current Ratio	3.59
Debt/Eq	0.03
LT Debt/Eq	0.02
Option/Short	No / Yes

EPS (ttm)	-3.20
EPS next Y	-0.57
EPS next Q	-
EPS this Y	47.06%
EPS next Y	9.52%
EPS next 5Y	22.68%
EPS past 3/5Y	72.98% 70.98%
Sales past 3/5Y	- -
EPS Y/Y TTM	78.51%
Sales Y/Y TTM	-
EPS Q/Q	58.93%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	0.00% -

Insider Own	3.63%
Insider Trans	8.13%
Inst Own	25.55%
Inst Trans	7.74%
ROA	-123.27%
ROE	-150.76%
ROIC	-211.13%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-0.26%
SMA50	-18.56%
SMA200	-12.16%
Trades

Shs Outstand	8.53M
Shs Float	8.22M
Short Float	10.11%
Short Ratio	0.18
Short Interest	0.83M
52W High	3.79 -64.91%
52W Low	0.82 62.20%
Volatility	9.72% 7.97%
ATR (14)	0.13
RSI (14)	45.85
Beta	0.80
Rel Volume	0.03
Avg Volume	4.52M
Volume	146,574

Perf Week	-2.92%
Perf Month	-17.13%
Perf Quarter	0.00%
Perf Half Y	-16.35%
Perf YTD	14.66%
Perf Year	-29.26%
Perf 3Y	-99.59%
Perf 5Y	-99.80%
Perf 10Y	-99.95%
Recom	1.00
Target Price	5.51
Prev Close	1.24
Price	1.33
Change %	7.26%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-22-22	Initiated	Cantor Fitzgerald	Overweight	$7
Jan-15-21	Initiated	B. Riley Securities	Buy	$47

Today 08:00AM	BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH's RECOVER-TLC Third Annual Workshop (GlobeNewswire) +7.26%
06:48AM	MARKETS LIVE: Wall Street rebounds as Anthropic IPO filing revives AI trade (Proactive)
Oct-20-26 09:53AM	BioVie reports positive Phase 2 Parkinsons data for bezisterim (Proactive) -9.49%
08:00AM	BioVie Presents Data on Bezisterim in Parkinson's Disease at the 2026 American Neurological Association Annual Meeting (GlobeNewswire)
07:05AM	MARKETS LIVE: Wall Street rebounds, FTSE loses ground ahead of Netflix earnings tonight (Proactive)
08:00AM	Loading…
Oct-19-26 08:00AM	BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting (GlobeNewswire) +14.17%
06:59AM	MARKETS LIVE: Nasdaq leads Wall Street higher as tech shares recover (Proactive)
Oct-14-26 09:50AM	BioVie to present Long COVID and Parkinsons trial results at American Neurological Association meeting (Proactive)
08:00AM	BioVie to Present New Bezisterim Findings in Parkinson's Disease and Long COVID at the 2026 American Neurological Association Annual Meeting (GlobeNewswire)
07:18AM	MARKETS LIVE: Nasdaq lower as inflation tops forecasts; FTSE closes higher (Proactive)
Sep-15-26 10:15AM	BioVie Shares Fall 9.7% After Long COVID Trial Misses Statistical Significance in Full Population (InvestorsHub) -14.63%
09:28AM	BioVie Phase 2 trial shows bezisterim eases fatigue, cognitive symptoms in severe Long COVID cases (Proactive)
07:35AM	Nasdaq drops as rising yields add to Wall Street pressure (Proactive)
07:30AM	BioVie Announces Topline Results from Phase 2 ADDRESS-LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID (GlobeNewswire)
Sep-14-26 04:01PM	BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid (GlobeNewswire) +6.22%
10:27AM	Loading…
Sep-10-26 10:27AM	BioVies lead therapy candidate shows improvement in key long COVID symptoms (Proactive)
Sep-08-26 10:10AM	Dow slides as oil nears $100, US-Canada trade tensions escalate (Proactive)
10:10AM	Dow closes sharply lower as oil surge fuels inflation fears (Proactive)
09:52AM	BioVie advances Parkinsons Phase 3 development program with FDA engagement (Proactive)
07:30AM	BioVie Announces Update to Parkinson's Phase 3 Development Program (GlobeNewswire)
Aug-31-26 09:48AM	Dow falls as US strikes Iran, rate-hike bets jump (Proactive) +5.56%
09:05AM	BioVie completes final patient visit in Phase 2 Long COVID trial (Proactive)
08:00AM	BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID (GlobeNewswire)
Aug-07-26 01:13PM	Parkinson's drug developers are betting big on inflammation (Proactive) -25.98%
07:05AM	BioVie stock sinks on Phase IIb Parkinsons trial data (Clinical Trials Arena)
Aug-06-26 09:03AM	BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim (Proactive) -33.82%
07:30AM	BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease (GlobeNewswire)
Aug-05-26 12:18PM	BioVie reports positive phase 2 Parkinson's results, eyes pivotal Phase 3 trial (Proactive) +11.48%
Jun-05-26 03:31PM	Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire) -6.98%
May-29-26 04:30PM	BioVie: Long COVID trial fully enrolled ICYMI (Proactive)
08:00AM	Loading…
May-27-26 08:00AM	Join BioVie's Exclusive Live Investor Webinar and Q and A Session on June 2 (GlobeNewswire)
May-26-26 01:34PM	BioVie completes enrollment in Long COVID trial as need for treatments grows (Proactive) -5.26%
09:12AM	BioVie completes enrollment in Phase 2 Long COVID trial (Proactive)
08:00AM	BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID (GlobeNewswire)
May-19-26 08:31AM	BioVie completes final patient visit in Parkinson's drug trial (Proactive)
May-18-26 08:00AM	BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's Disease (GlobeNewswire)
May-09-26 09:00AM	BioVie CEO shares insights into long COVID trial - ICYMI (Proactive)
May-04-26 11:24AM	BioVie advances long COVID trial, top-line data expected by summer (Proactive)
Apr-27-26 08:00AM	BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026 (GlobeNewswire) +6.00%
Apr-14-26 08:00AM	BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting (GlobeNewswire) +5.80%
05:10AM	BioVie abstract on Parkinsons drug accepted for neurology conference (Proactive)
03:52AM	Nasdaq jumps, Dow heads higher with Iran talks and earnings in focus (Proactive)
Apr-11-26 07:27AM	BioVie CEO explains Bezisterim Parkinsons trial results - ICYMI (Proactive)
Apr-09-26 01:44PM	BioVie targets neuroinflammation and insulin resistance in Parkinsons treatment approach (Proactive)
Mar-26-26 11:00AM	BioVie targets Parkinsons at its source with lead drug bezisterim (Proactive)
Mar-12-26 09:05AM	BioVie to present Parkinsons study data at AD/PD 2026 conference (Proactive)
08:00AM	BioVie Announces Abstract Accepted for Presentation at AD/PD 2026 (GlobeNewswire)
Feb-23-26 08:00AM	Join Biovie's Exclusive Live Investor Webinar and Q&A Session on March 4 (GlobeNewswire)
Feb-12-26 03:50PM	Dow drops below 50,000 as S&P 500 falls back under years opening level (Proactive)
08:33AM	BioVie highlights bezisterim research at ACP meeting (Proactive)
08:00AM	BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting (GlobeNewswire)
Feb-11-26 10:30AM	BioVie could offer first new Parkinsons therapy in decades (Proactive)
Jan-08-26 08:00AM	BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson's Disease (GlobeNewswire)
Dec-24-25 02:05PM	HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
Dec-11-25 12:00PM	What Makes BioVie (BIVI) a New Buy Stock (Zacks)
Nov-19-25 08:00AM	Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9 (GlobeNewswire)
Oct-24-25 08:20AM	Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Sep-26-25 08:00AM	BioVie to Host Live Investor Webinar and Q&A on Oct. 8 (GlobeNewswire)
Aug-13-25 04:05PM	BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes (GlobeNewswire)
Aug-11-25 04:05PM	BioVie Inc. Announces Closing of $12 Million Public Offering (GlobeNewswire) +7.19% -6.70%
Aug-07-25 08:43PM	BioVie Inc. Announces Pricing of $12 Million Public Offering (GlobeNewswire) -25.58% -42.61%
Jul-24-25 08:00AM	BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology (GlobeNewswire) -8.37%
Jul-22-25 08:00AM	BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors (GlobeNewswire) +12.04%
Jul-09-25 08:00AM	BioVie Announces Data Highlighting Bezisterim's Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference (GlobeNewswire)
Jun-26-25 08:00AM	BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders Congress (ATMRD) (GlobeNewswire)
Jun-24-25 04:05PM	BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders Congress (GlobeNewswire) +5.94%
May-15-25 08:00AM	BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID (GlobeNewswire)
May-14-25 07:30AM	BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025 (GlobeNewswire)
May-07-25 08:00AM	BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025) (GlobeNewswire) -6.90%
May-05-25 08:00AM	BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth (GlobeNewswire) -5.79%
Apr-16-25 08:00AM	BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson's Disease with First Patient Enrolled (GlobeNewswire)
Mar-27-25 08:00AM	BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025 (GlobeNewswire)
Mar-10-25 10:35AM	New to The Street Show 633 to Broadcast on Fox Business Network as Sponsored Programming Tonight at 10:30 PM PST Featuring Zapp Electric Vehicles ($ZAPP), BioVie ($BIVI), PetVivo ($PETV), and Banzai ($BNZI) (ACCESS Newswire) -8.40%
Mar-03-25 08:40PM	New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With Craig Bruce (ACCESS Newswire) -11.28%
Feb-22-25 12:15PM	New to The Street to Broadcast Live on Bloomberg Tonight at 6:30 PM EST as Sponsored Programming, Spotlighting BioVie (BIVI), RoadZen (RDZN), HPB, and Sustainable Innovation With Shark Tanks Kevin Harrington and Sustainable Green Team (SGTM) (ACCESS Newswire)
Jan-13-25 09:00AM	BioVie Inc. ($BIVI) Joins Forces With New to The Street for a Dynamic 6-Part Media Campaign Featuring Long-Form Interviews, National TV Commercials, Iconic Billboards, and Exclusive Accredited Events (ACCESS Newswire)
Nov-20-24 08:00AM	BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference (GlobeNewswire)
Nov-04-24 08:00AM	BioVie's Upcoming Parkinson's Disease Clinical Trial is Fully Funded (GlobeNewswire) -9.39%
Oct-29-24 04:05PM	BioVie Inc. Announces Closing of Registered Direct Offering (GlobeNewswire) -10.80% +10.94%
Oct-28-24 04:10PM	UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
03:13PM	BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-24-24 04:10PM	BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) +5.45% +5.54%
Oct-23-24 03:24PM	BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -23.51%
09:19AM	BioVie Announces Stock Offering and Private Placement (TipRanks)
08:00AM	Join BioVie's Exclusive Live Investor Webinar and Q&A Session on November 7th, 2024 (GlobeNewswire)
Oct-22-24 04:01PM	BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) +27.76%
Oct-21-24 03:08PM	BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +11.91%
Oct-15-24 08:00AM	BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin (GlobeNewswire)
Oct-11-24 09:00AM	BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Oct-01-24 08:00AM	BioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin (GlobeNewswire)
Sep-25-24 04:05PM	BioVie Inc. Announces Closing of Public Offering (GlobeNewswire) -7.50%
Sep-23-24 10:26PM	BioVie Inc. Announces Pricing of Public Offering (GlobeNewswire) -57.86%
04:05PM	BioVie Inc. Announces Proposed Public Offering (GlobeNewswire)
Sep-16-24 08:00AM	BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID (GlobeNewswire)
Sep-03-24 08:00AM	BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID (GlobeNewswire)
Aug-27-24 08:45AM	BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting (GlobeNewswire)
Aug-13-24 08:00AM	BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting (GlobeNewswire)
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -10.08%
Aug-08-24 06:00AM	BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease (GlobeNewswire) +13.30%
Aug-06-24 04:40PM	BioVie Inc. Announces Reverse Stock Split (GlobeNewswire) -21.40% -5.63%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Palumbo Joseph M	Chief Medical Officer	Aug 28 '26	Buy	2.16	4,843	10,461	6,036	Aug 28 09:01 PM
Chappell Amy Suzon	Director	Aug 28 '26	Buy	2.16	727	1,570	727	Aug 28 09:01 PM
KIM JOANNE WENDY	Chief Financial Officer	Aug 28 '26	Buy	2.18	2,500	5,450	3,441	Aug 28 08:58 PM
DO CUONG V	President & CEO	Aug 27 '26	Buy	2.08	15,210	31,637	16,117	Aug 28 08:57 PM

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders, and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

PresidentMr. Cuong Viet Do M.B.A.

CFOMs. Joanne Wendy Kim C.P.A.

Executive VP of R&D and Chief Medical OfficerDr. Joseph M. Palumbo M.D.

Senior Vice President of OperationsMr. Clarence N. Ahlem

Senior Vice President of Liver Disease & Long COVID ProgramsDr. Penelope Markham Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BIVI

BioVie Inc

Upgrade your Finviz experience